Half-year report · Q2
4578.TEDINET S100U5FO
Period2024-01-01 → 2024-06-30
Filed2024-08-02
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 56
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.11T | 2024-01-01 → 2024-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥589.4bn | 2024-04-01 → 2024-06-30d | Cons. | Revenue IFRS |
| Revenue | ¥2.02T | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥947.5bn | 2023-01-01 → 2023-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥499.2bn | 2023-04-01 → 2023-06-30d | Cons. | Revenue IFRS |
| Operating income | ¥126.3bn | 2024-01-01 → 2024-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥34.3bn | 2024-04-01 → 2024-06-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥130.7bn | 2023-01-01 → 2023-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥53.9bn | 2023-04-01 → 2023-06-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥142.2bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥42.1bn | 2024-04-01 → 2024-06-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥142.7bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥138.8bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥59.6bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥107.8bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥30.4bn | 2024-04-01 → 2024-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥121.6bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥102.6bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥41.2bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥110.6bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥31.7bn | 2024-04-01 → 2024-06-30d | Cons. | Profit loss IFRS |
| Net income | ¥105.1bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥42.4bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss IFRS |
| Total assets | ¥3.66T | at 2024-06-30 | Cons. | Assets IFRS |
| Total assets | ¥3.36T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.31T | at 2023-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥993.9bn | at 2024-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥924.9bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥2.67T | at 2024-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.44T | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.47T | at 2023-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.26T | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥2.62T | at 2024-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.39T | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.43T | at 2023-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥485.9bn | at 2024-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥513.3bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥498.7bn | at 2023-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥471.6bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥133.0bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥283.2bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥113.5bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥159.2bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥190.5bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥54.3bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥26.2bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥60.3bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥46.8bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥198.61 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥56.03 | 2024-04-01 → 2024-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥224.1 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥189.06 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥75.85 | 2023-04-01 → 2023-06-30d | Cons. | Basic earnings loss per share IFRS |
| Equity ratio | 71.6% | at 2024-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.2% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 73.4% | at 2023-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 88
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-06-30 | ¥56.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-06-30 | ¥29.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-06-30 | ¥54.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-06-30 | ¥28.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-06-30 | ¥880m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-06-30 | ¥4.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-06-30 | ¥2.9bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-06-30 | −¥1.8bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-06-30 | −¥890m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-06-30 | −¥1.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-06-30 | −¥890m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-06-30 | −¥24.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-06-30 | −¥13.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥15.7bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2024-04-01 → 2024-06-30 | ¥8.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥15.7bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2024-04-01 → 2024-06-30 | ¥8.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥3m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2024-04-01 → 2024-06-30 | ¥1m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥12.3bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2024-04-01 → 2024-06-30 | ¥8.0bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥271.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2024-04-01 → 2024-06-30 | ¥145.6bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥271.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2024-04-01 → 2024-06-30 | ¥145.6bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥15m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2024-04-01 → 2024-06-30 | ¥8m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥37.3bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2024-04-01 → 2024-06-30 | ¥20.5bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥766.7bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2024-04-01 → 2024-06-30 | ¥407.1bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥766.7bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2024-04-01 → 2024-06-30 | ¥407.1bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥96.0bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2024-04-01 → 2024-06-30 | ¥16.2bn |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥1.11T |
| —segment total | revenue | 2024-04-01 → 2024-06-30 | ¥590.3bn |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥1.11T |
| —segment total | revenue external | 2024-04-01 → 2024-06-30 | ¥589.4bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥1.8bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-06-30 | ¥890m |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | ¥150.5bn |
| —segment total | segment profit | 2024-04-01 → 2024-06-30 | ¥47.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-06-30 | ¥55.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-06-30 | ¥27.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-06-30 | ¥53.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-06-30 | ¥26.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥1.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥920m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-06-30 | ¥4.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-06-30 | ¥1.5bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-06-30 | −¥1.7bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥965m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-06-30 | −¥1.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥965m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-06-30 | −¥25.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥12.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥17.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥9.2bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥17.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥9.2bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥9m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥4m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥8.1bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥5.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥226.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥122.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥226.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥122.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥54m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥40m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥7.0bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥3.8bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥650.4bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥340.9bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥650.4bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥340.9bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥136.3bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥62.7bn |
| —segment total | revenue | 2023-01-01 → 2023-06-30 | ¥949.2bn |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥500.2bn |
| —segment total | revenue external | 2023-01-01 → 2023-06-30 | ¥947.5bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥499.2bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥1.7bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥965m |
| —segment total | segment profit | 2023-01-01 → 2023-06-30 | ¥156.1bn |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥66.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 877
| Item | Context | Value | Unit |
|---|---|---|---|
| Contract liabilities ncl IFRS | CurrentQuarterInstant | 40487000000 | JPY |
| Deferred tax liabilities IFRS | Prior1YearInstant | 27170000000 | JPY |
| Deferred tax liabilities IFRS | CurrentQuarterInstant | 29092000000 | JPY |
| Other non current liabilities ncl IFRS | Prior1YearInstant | 24152000000 | JPY |
| Other non current liabilities ncl IFRS | CurrentQuarterInstant | 32774000000 | JPY |
| Non current labilities IFRS | Prior1YearInstant | 257692000000 | JPY |
| Non current labilities IFRS | CurrentQuarterInstant | 270033000000 | JPY |
| Liabilities IFRS | Prior1YearInstant | 924926000000 | JPY |
| Liabilities IFRS | CurrentQuarterInstant | 993857000000 | JPY |
| Share capital IFRS | Prior1YearInstant | 81690000000 | JPY |
| Share capital IFRS | CurrentQuarterInstant | 81690000000 | JPY |
| Capital surplus IFRS | Prior1YearInstant | 506230000000 | JPY |
| Capital surplus IFRS | CurrentQuarterInstant | 505692000000 | JPY |
| Treasury shares IFRS | Prior1YearInstant | -44669000000 | JPY |
| Treasury shares IFRS | CurrentQuarterInstant | -43608000000 | JPY |
| Retained earnings IFRS | Prior1YearInstant | 1621218000000 | JPY |
| Retained earnings IFRS | CurrentQuarterInstant | 1697511000000 | JPY |
| Other components of equity IFRS | Prior1YearInstant | 229214000000 | JPY |
| Other components of equity IFRS | CurrentQuarterInstant | 380542000000 | JPY |
| Equity attributable to owners of parent IFRS | Prior1YearInstant | 2393683000000 | JPY |
| Equity attributable to owners of parent IFRS | CurrentQuarterInstant | 2621829000000 | JPY |
| Non controlling interests IFRS | Prior1YearInstant | 42634000000 | JPY |
| Non controlling interests IFRS | CurrentQuarterInstant | 44943000000 | JPY |
| Equity IFRS | Prior1YearInstant | 2436317000000 | JPY |
| Equity IFRS | CurrentQuarterInstant | 2666772000000 | JPY |
| Liabilities and equity IFRS | Prior1YearInstant | 3361244000000 | JPY |
| Liabilities and equity IFRS | CurrentQuarterInstant | 3660630000000 | JPY |
| Revenue IFRS | Prior1YTDDuration | 947537000000 | JPY |
| Revenue IFRS | CurrentYTDDuration | 1108930000000 | JPY |
| Cost of sales IFRS | Prior1YTDDuration | 287862000000 | JPY |
| Cost of sales IFRS | CurrentYTDDuration | 316211000000 | JPY |
| Gross profit IFRS | Prior1YTDDuration | 659674000000 | JPY |
| Gross profit IFRS | CurrentYTDDuration | 792718000000 | JPY |
| Selling general and administrative expenses IFRS | Prior1YTDDuration | 372283000000 | JPY |
| Selling general and administrative expenses IFRS | CurrentYTDDuration | 453722000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | 9759000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration | 18575000000 | JPY |
| Research and development expenditure recognized as expense during period IFRS | Prior1YTDDuration | 142103000000 | JPY |
| Research and development expenditure recognized as expense during period IFRS | CurrentYTDDuration | 143949000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration | 28929000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration | 104076000000 | JPY |
| Other income IFRS | Prior1YTDDuration | 5580000000 | JPY |
| Other income IFRS | CurrentYTDDuration | 17383000000 | JPY |
| Other expenses IFRS | Prior1YTDDuration | 1006000000 | JPY |
| Other expenses IFRS | CurrentYTDDuration | 650000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 130690000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | 126279000000 | JPY |
| Finance income IFRS | Prior1YTDDuration | 10538000000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 20581000000 | JPY |
| Finance costs IFRS | Prior1YTDDuration | 2395000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |